Objective: To evaluate real-world glycemic outcomes and insulin delivery based on TIR (70-180mg/dL) before and after MiniMed™ 780G system use by children with T1D.

Methods: MiniMed™ 780G system data from 2,516 users aged ≤15 years (from Europe, the Middle East and Africa) who provided assent, were uploaded between Aug 2020 and Jun 2022. For users with ≥10 days of sensor glucose (SG) data, glycemic outcomes (e.g., SG, time in SG ranges and glucose management indicator [GMI]), insulin delivered, and use of the 100mg/dL* glucose target and 2hrs active insulin time (recommended settings) were summarized and stratified by baseline TIR quartiles. Results: After AHCL initiation, overall glycemic control (GMI) improved and TIR increased in all TIR quartiles, with increased system-initiated insulin (auto basal and auto correction) delivery and fewer user-initiated boluses (Figure). Greater recommended settings use was associated with a higher TIR (4th quartile) and less recommended settings use was associated with a lower TIR (1st quartile).

Conclusion: Children with T1D using the MiniMed™ 780G system had improved glycemic control evidenced by increased TIR with less effort (i.e., fewer user-initiated boluses). Glycemic control was improved across the spectrum of users and use of recommended settings enhanced outcomes.


J.Mcvean: Employee; Medtronic. A.Arrieta: Employee; Medtronic. T.L.Cordero: Employee; Medtronic. J.Castañeda: Employee; Medtronic. O.Cohen: Employee; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.